Citation

Xue R, Zhang YZ, Zou LB. Chinese Pharmacological Bulletin 2008; 24(12): 1558-1561.

Copyright

(Copyright © 2008)

DOI

unavailable

PMID

unavailable

Abstract

Existing antidepressants exhibit delayed onset of action, which can decrease the compliance of the patients and enhance the risk of suicide. How to produce early-onset antidepressants with higher efficacy and lower adverse reactions has become a crucial point in the research of antidepressants. It has been demonstrated that selective 5-HT1A antagonist, α2 antagonist and 5-HT2A antagonist can accelerate the response of classic antidepressants. Furthermore,5-HT/NE dual reuptake inhibitor and 5-HT/NE/DA triple reuptake inhibitor can also produce early onset of action. Here several reasons for the delayed onset of action and the progress in the development of early-onset antidepressants are reviewed.

Language: zh

Keywords

human; depression; mood disorder; Antidepressant; article; antidepressant agent; amfebutamone; citalopram; fluoxetine; mirtazapine; monoamine oxidase inhibitor; nefazodone; noradrenalin uptake inhibitor; serotonin uptake inhibitor; sertraline; tricyclic antidepressant agent; dopamine uptake inhibitor; drug mechanism; reboxetine; nonhuman; drug potentiation; drug efficacy; risperidone; duloxetine; methylphenidate; drug response; Onset of action; serotonin 2A antagonist; drug design; serotonin noradrenalin reuptake inhibitor; n [2 [4 (2 methoxyphenyl) 1 piperazinyl]ethyl] n (2 pyridyl)cyclohexanecarboxamide; volinanserin; 2 [[(7 fluoro 4 indanyl)oxy]methyl]morpholine; 5-HT1A antagonist; 5-HT2A antagonist; Dual/triple reuptake inhibitors; robalzotan; serotonin 1A antagonist; vilazodone; α2 antagonist